Earnings Scheduled For February 9, 2022
Companies Reporting Before The Bell
• Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion.
Needham Maintains Buy on Seagen, Lowers Price Target to $200
Needham analyst Ami Fadia maintains Seagen (NASDAQ:SGEN) with a Buy and lowers the price target from $254 to $200.
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big pharma earnings. The sector came back up in the final session for a firm finish.
Morgan Stanley Upgrades Seagen to Overweight, Announces $175 Price Target
Morgan Stanley analyst Matthew Harrison upgrades Seagen (NASDAQ:SGEN) from Equal-Weight to Overweight and announces $175 price target.
Will Chart Analysts Notice Bad Omen on Seagen’s Chart
If history is any guide, there may be trouble ahead for shares of Seagen (NASDAQ:SGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Seagen’s SEA-CD40 Combo Regime Shows Preliminary Antitumor Activity In Pancreatic Cancer
Seagen Inc (NASDAQ: SGEN)
Seagen Reports Data From SEA-CD40 In Combination With Other Therapies In Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) At American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Seagen Inc. (NASDAQ:SGEN) today announced data from a phase 1 clinical trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic PDAC at the ASCO GI annual meeting taking place in San
Where Seagen Stands With Analysts
Within the last quarter, Seagen (NASDAQ: SGEN) has observed the following analyst ratings:
Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings:
Morgan Stanley Maintains Equal-Weight on Seagen, Lowers Price Target to $178
Morgan Stanley maintains Seagen (NASDAQ:SGEN) with a Equal-Weight and lowers the price target from $181 to $178.